默沙东(Merck)表示,宣布暂停向中国供应HPV疫苗Gardasil,预计将持续至少到今年年中,这一举措对公司的销售预期产生了负面影响。
该公司声明称,作为默沙东产品组合中的重要产品,这款用于预防癌症的Gardasil疫苗在中国的需求出现下滑,导致公司业绩展望显著下调,目前预计将在2025年实现641亿美元至656亿美元的销售额。这一数字低于华尔街分析师平均预期的674亿美元。
截至发稿,默沙东美股盘前跌超8%,报91.5美元。
责任编辑:刘明亮
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.